Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Revolution Medicines' daraxonrasib doubled survival in advanced pancreatic cancer, extending median survival to 13.2 months versus 6.7 months with chemotherapy in a Phase 3 trial.

Immuneering's atebimetinib plus chemotherapy showed 94% six-month and 86% nine-month survival—well above standard-of-care benchmarks of about 67% and 47% respectively.

Actuate Therapeutics' elraglusib plus chemotherapy doubled the one-year survival rate (44% vs 22%) and extended median survival by about three months (10.1 vs 7.2 months) in a Phase II trial, cutting the risk of death by about 37%.

Sources:

Can Revolution's 'miracle' pancreatic cancer drug be topped ...

Novel Drug Promising Clinical Trial - Let's Win Pancreatic Cancer

Actuate Therapeutics: Targeting Hard-to-Treat Cancers

FDA expands access to pancreatic cancer drug helping patients like ...

New Drug Doubles One-Year Survival in Pancreatic Cancer Trial

Ben Sasse grateful to be in Rev Med's pancreatic cancer drug trial

Our Story | Building a New Standard in Cancer Care - Immuneering

Actuate's pancreatic cancer drug boosts survival by 3 months

Immuneering touts 64% survival, fueling race with Revolution

Revolution Medicines touts success in pancreatic cancer treatment

Immuneering progresses MAPK inhibitor in lung and pancreatic ...

Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial